Research ExplorerPublicationsEdwards Sapien XT valve placement as treatment option for ao...

Edwards Sapien XT valve placement as treatment option for aortic regurgitation after transfemoral CoreValve implantation: a multicenter experience

Standard

Edwards Sapien XT valve placement as treatment option for aortic regurgitation after transfemoral CoreValve implantation: a multicenter experience. / Diemert, Patrick; Lange, Philipp; Greif, Martin; Seiffert, Moritz; Conradi, Lenard; Massberg, Steffen; Blankenberg, Stefan; Reichenspurner, Hermann; Hagl, Christian; Schmitz, Christoph; Schröfel, Holger; Treede, Hendrik; Schymik, Gerhard; Kupatt, Christian.

In: CLIN RES CARDIOL, Vol. 103, No. 3, 03.2014, p. 183-190.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Diemert, P, Lange, P, Greif, M, Seiffert, M, Conradi, L, Massberg, S, Blankenberg, S, Reichenspurner, H, Hagl, C, Schmitz, C, Schröfel, H, Treede, H, Schymik, G & Kupatt, C 2014, 'Edwards Sapien XT valve placement as treatment option for aortic regurgitation after transfemoral CoreValve implantation: a multicenter experience', CLIN RES CARDIOL, vol. 103, no. 3, pp. 183-190. https://doi.org/10.1007/s00392-013-0632-8

APA

Diemert, P., Lange, P., Greif, M., Seiffert, M., Conradi, L., Massberg, S., Blankenberg, S., Reichenspurner, H., Hagl, C., Schmitz, C., Schröfel, H., Treede, H., Schymik, G., & Kupatt, C. (2014). Edwards Sapien XT valve placement as treatment option for aortic regurgitation after transfemoral CoreValve implantation: a multicenter experience. CLIN RES CARDIOL, 103(3), 183-190. https://doi.org/10.1007/s00392-013-0632-8

Vancouver

Diemert P, Lange P, Greif M, Seiffert M, Conradi L, Massberg S et al. Edwards Sapien XT valve placement as treatment option for aortic regurgitation after transfemoral CoreValve implantation: a multicenter experience. CLIN RES CARDIOL. 2014 Mar;103(3):183-190. https://doi.org/10.1007/s00392-013-0632-8

Bibtex

@article{badace41181c438abbf1a4e7f3f69116,
title = "Edwards Sapien XT valve placement as treatment option for aortic regurgitation after transfemoral CoreValve implantation: a multicenter experience",
abstract = "UNLABELLED: Transcatheter aortic valve replacement (TAVI), though a preferred treatment option in the elderly population carrying increased risks for open heart surgery, may result in prognosis-limiting moderate or severe aortic regurgitation. Here, we report a series of 11 patients from 3 German TAVI centers, suffering from moderate- to high-grade aortic regurgitation after CoreValve implantation, who were subsequently treated by Edwards Sapien XT implantation.METHODS: The patients were 79.5 ± 4.2 years of age and presented between November 2009 and February 2013 with a symptomatic high-grade aortic stenosis (mean maximum gradient 57 ± 22 mmHg) and EuroSCORE of 16 ± 7%. Initial implantation of a Medtronic CoreValve resulted in moderate-to-severe aortic regurgitation (grade 2.64 ± 0.37) although postdilatation was attempted in eight cases and snare repositioning was attempted in one case.RESULTS: All 11 patients were treated by a Sapien XT (Edwards) valve implanted into the initially deployed CoreValve: four via transfemoral, one via transaortical and six via transapical approaches. Successful implantation was possible in all 11 patients resulting in a reduction of aortic regurgitation to mean grade 0.23 ± 0.39. Two patients required permanent pacemaker. After 30 days, ten patients were alive, whereas one patient succumbed to pneumonia complicating advanced chronic obstructive pulmonary disease.CONCLUSION: In the instance of moderate or severe aortic regurgitation after TAVI of a CoreValve, transfemoral or transapical Sapien XT valve-in-valve deployment is an excellent option to reduce residual regurgitation to none or mild.",
keywords = "Aged, Aged, 80 and over, Aortic Valve Insufficiency/diagnosis, Aortic Valve Stenosis/diagnosis, Cardiac Catheterization/adverse effects, Echocardiography, Doppler, Color, Female, Femoral Artery, Germany, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation/adverse effects, Humans, Male, Prosthesis Design, Retrospective Studies, Severity of Illness Index, Time Factors, Treatment Outcome",
author = "Patrick Diemert and Philipp Lange and Martin Greif and Moritz Seiffert and Lenard Conradi and Steffen Massberg and Stefan Blankenberg and Hermann Reichenspurner and Christian Hagl and Christoph Schmitz and Holger Schr{\"o}fel and Hendrik Treede and Gerhard Schymik and Christian Kupatt",
year = "2014",
month = mar,
doi = "10.1007/s00392-013-0632-8",
language = "English",
volume = "103",
pages = "183--190",
journal = "CLIN RES CARDIOL",
issn = "1861-0684",
publisher = "D. Steinkopff-Verlag",
number = "3",

}

RIS

TY - JOUR

T1 - Edwards Sapien XT valve placement as treatment option for aortic regurgitation after transfemoral CoreValve implantation: a multicenter experience

AU - Diemert, Patrick

AU - Lange, Philipp

AU - Greif, Martin

AU - Seiffert, Moritz

AU - Conradi, Lenard

AU - Massberg, Steffen

AU - Blankenberg, Stefan

AU - Reichenspurner, Hermann

AU - Hagl, Christian

AU - Schmitz, Christoph

AU - Schröfel, Holger

AU - Treede, Hendrik

AU - Schymik, Gerhard

AU - Kupatt, Christian

PY - 2014/3

Y1 - 2014/3

N2 - UNLABELLED: Transcatheter aortic valve replacement (TAVI), though a preferred treatment option in the elderly population carrying increased risks for open heart surgery, may result in prognosis-limiting moderate or severe aortic regurgitation. Here, we report a series of 11 patients from 3 German TAVI centers, suffering from moderate- to high-grade aortic regurgitation after CoreValve implantation, who were subsequently treated by Edwards Sapien XT implantation.METHODS: The patients were 79.5 ± 4.2 years of age and presented between November 2009 and February 2013 with a symptomatic high-grade aortic stenosis (mean maximum gradient 57 ± 22 mmHg) and EuroSCORE of 16 ± 7%. Initial implantation of a Medtronic CoreValve resulted in moderate-to-severe aortic regurgitation (grade 2.64 ± 0.37) although postdilatation was attempted in eight cases and snare repositioning was attempted in one case.RESULTS: All 11 patients were treated by a Sapien XT (Edwards) valve implanted into the initially deployed CoreValve: four via transfemoral, one via transaortical and six via transapical approaches. Successful implantation was possible in all 11 patients resulting in a reduction of aortic regurgitation to mean grade 0.23 ± 0.39. Two patients required permanent pacemaker. After 30 days, ten patients were alive, whereas one patient succumbed to pneumonia complicating advanced chronic obstructive pulmonary disease.CONCLUSION: In the instance of moderate or severe aortic regurgitation after TAVI of a CoreValve, transfemoral or transapical Sapien XT valve-in-valve deployment is an excellent option to reduce residual regurgitation to none or mild.

AB - UNLABELLED: Transcatheter aortic valve replacement (TAVI), though a preferred treatment option in the elderly population carrying increased risks for open heart surgery, may result in prognosis-limiting moderate or severe aortic regurgitation. Here, we report a series of 11 patients from 3 German TAVI centers, suffering from moderate- to high-grade aortic regurgitation after CoreValve implantation, who were subsequently treated by Edwards Sapien XT implantation.METHODS: The patients were 79.5 ± 4.2 years of age and presented between November 2009 and February 2013 with a symptomatic high-grade aortic stenosis (mean maximum gradient 57 ± 22 mmHg) and EuroSCORE of 16 ± 7%. Initial implantation of a Medtronic CoreValve resulted in moderate-to-severe aortic regurgitation (grade 2.64 ± 0.37) although postdilatation was attempted in eight cases and snare repositioning was attempted in one case.RESULTS: All 11 patients were treated by a Sapien XT (Edwards) valve implanted into the initially deployed CoreValve: four via transfemoral, one via transaortical and six via transapical approaches. Successful implantation was possible in all 11 patients resulting in a reduction of aortic regurgitation to mean grade 0.23 ± 0.39. Two patients required permanent pacemaker. After 30 days, ten patients were alive, whereas one patient succumbed to pneumonia complicating advanced chronic obstructive pulmonary disease.CONCLUSION: In the instance of moderate or severe aortic regurgitation after TAVI of a CoreValve, transfemoral or transapical Sapien XT valve-in-valve deployment is an excellent option to reduce residual regurgitation to none or mild.

KW - Aged

KW - Aged, 80 and over

KW - Aortic Valve Insufficiency/diagnosis

KW - Aortic Valve Stenosis/diagnosis

KW - Cardiac Catheterization/adverse effects

KW - Echocardiography, Doppler, Color

KW - Female

KW - Femoral Artery

KW - Germany

KW - Heart Valve Prosthesis

KW - Heart Valve Prosthesis Implantation/adverse effects

KW - Humans

KW - Male

KW - Prosthesis Design

KW - Retrospective Studies

KW - Severity of Illness Index

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1007/s00392-013-0632-8

DO - 10.1007/s00392-013-0632-8

M3 - SCORING: Journal article

C2 - 24249313

VL - 103

SP - 183

EP - 190

JO - CLIN RES CARDIOL

JF - CLIN RES CARDIOL

SN - 1861-0684

IS - 3

ER -